Literature DB >> 18246392

Laparoscopic splenectomy for splenic masses.

D J Tessier1, R A Pierce, L M Brunt, V J Halpin, J C Eagon, M M Frisella, S Czerniejewski, B D Matthews.   

Abstract

BACKGROUND: This study aimed to evaluate the perioperative outcomes and pathology of patients undergoing laparoscopic splenectomy for splenic masses.
METHODS: The records for 174 patients who underwent laparoscopic splenectomy from May 1994 to August 2006 were reviewed. Patient demographics, preoperative imaging, American Society of Anesthesiologists (ASA) score, body mass index (BMI), estimated blood loss (EBL), operative time, spleen size, complications, hospital length of stay (LOS), pathology, and mortality were extracted from the records. Data are expressed as means +/- standard deviation. Statistical significance (p < 0.05) was determined using a two-tailed t-test and Fisher's exact test.
RESULTS: A splenic mass was diagnosed preoperatively for 18 patients (10.3%) (7 males and 11 females). The mean patient age was 51.4 +/- 13.7 years. The mean ASA was 2.3 +/- 0.8, and the mean BMI was 27.3 +/- 5.8 kg/m(2). Computed tomography scans demonstrated splenic masses in all the patients. The mean mass size was 4.3 +/- 3.3 cm (range, 1.0-11.0 cm), and the mean spleen length was 14.6 +/- 7.5 cm (range, 5.5-40.2 cm). Total laparoscopic splenectomy was completed for 15 patients, and hand-assisted splenectomy was performed for 3 patients (2 converted). The mean operative time was 128.3 +/- 38.5 min, and the mean EBL was 110 +/- 137.5 ml. There were no intraoperative complications or 30-day mortalities. The postoperative complication rate was 11.1%, and the mean LOS was 1.9 +/- 1.0 days. The pathology for six patients (33.3%) was malignant (5 lymphomas and 1 adenocarcinoma). There were three false-positive positron emission tomography (PET) scans. Compared with 73 patients undergoing laparoscopic splenectomy for idiopathic thrombocytopenic purpura, there was no significant difference in mean EBL, operative time, conversion rate, complication rate, LOS, or 30-day mortality rate (p > 0.05).
CONCLUSIONS: Laparoscopic splenectomy is appropriate for patients whose indication for surgery is splenic mass. Suspicious splenic masses should be removed due to the relatively high incidence of malignant pathology, most commonly lymphoma.

Entities:  

Mesh:

Year:  2008        PMID: 18246392     DOI: 10.1007/s00464-008-9748-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  Inflammatory pseudotumor of the spleen: a case report.

Authors:  H Noguchi; H Kondo; M Kondo; M Shiraiwa; Y Monobe
Journal:  Jpn J Clin Oncol       Date:  2000-04       Impact factor: 3.019

Review 2.  Laparoscopic splenectomy: present status and future perspective.

Authors:  Charles F Bellows; John F Sweeney
Journal:  Expert Rev Med Devices       Date:  2006-01       Impact factor: 3.166

3.  Imaging-guided percutaneous biopsy of focal splenic lesions: update on safety and effectiveness.

Authors:  M T Keogan; K S Freed; E K Paulson; R C Nelson; L G Dodd
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

Review 4.  Splenic malignancy: a minimally invasive approach.

Authors:  Miguel Burch; Monali Misra; Edward H Phillips
Journal:  Cancer J       Date:  2005 Jan-Feb       Impact factor: 3.360

5.  Use of fine-needle aspiration biopsy in the evaluation of splenic lesions in a cancer center.

Authors:  N P Caraway; C V Fanning
Journal:  Diagn Cytopathol       Date:  1997-04       Impact factor: 1.582

6.  Management of abdominal lymphoproliferative diseases in the era of laparoscopy.

Authors:  G Silecchia; A Fantini; L Raparelli; A De Leo; D Vitolo; B Monarca; M Bezzi; P Rosato; N Basso
Journal:  Am J Surg       Date:  1999-04       Impact factor: 2.565

7.  Nontraumatic focal lesions of the spleen: assessment of imaging and clinical evaluation.

Authors:  P L Caslowitz; J D Labs; E K Fishman; S S Siegelman
Journal:  Comput Med Imaging Graph       Date:  1990 Mar-Apr       Impact factor: 4.790

8.  A comparison of laparoscopically assisted and open colectomy for colon cancer.

Authors:  Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

9.  Hand-assisted laparoscopic splenectomy for splenic tumors.

Authors:  Hiroshi Yano; Yoshiaki Nakano; Takeshi Tono; Tadashi Ohnishi; Takashi Iwazawa; Yutaka Kimura; Toshiyuki Kanoh; Takushi Monden
Journal:  Dig Surg       Date:  2004-06-25       Impact factor: 2.588

10.  Malignant lymphoma presenting with prominent splenomegaly. A clinicopathologic study with special reference to intermediate cell lymphoma.

Authors:  S Narang; B C Wolf; R S Neiman
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

View more
  5 in total

1.  Laparoscopic splenectomy: a surgeon's experience of 302 patients with analysis of postoperative complications.

Authors:  Xin Wang; Yongbin Li; Nicolas Crook; Bing Peng; Ting Niu
Journal:  Surg Endosc       Date:  2013-08-24       Impact factor: 4.584

2.  Splenic lymphoma with massive splenomegaly: Case report with review of literature.

Authors:  Sachin B Ingle; Chitra R Hinge Ingle
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

3.  Laparoscopic splenectomy for splenic hamartoma: Case management and clinical consequences.

Authors:  Tsutomu Namikawa; Hiroyuki Kitagawa; Jun Iwabu; Michiya Kobayashi; Manabu Matsumoto; Kazuhiro Hanazaki
Journal:  World J Gastrointest Surg       Date:  2010-04-27

4.  Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.

Authors:  Zhong Wu; Jin Zhou; Xin Wang; Yong-Bin Li; Ting Niu; Bing Peng
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

5.  Primary splenic lymphoma: Current diagnostic trends.

Authors:  Sachin B Ingle; Chitra R Hinge Ingle
Journal:  World J Clin Cases       Date:  2016-12-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.